In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 47 for your search:

Drug:  exemestane
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Phase: Phase IV
Type: Natural history/Epidemiology
Status: Enrolling by invitation
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: A5991089, NCT01047358

A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer

Phase: Phase IV
Type: Natural history/Epidemiology
Status: Closed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: A5991091, NCT01121549

Phase II/III Randomized Study of Neoadjuvant Therapy Comprising Exemestane Versus Letrozole Versus Anastrozole in Postmenopausal Women With Estrogen Receptor Positive Stage II or III Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor: NCI
Protocol IDs: ACOSOG-Z1031, CALGB-ACOSOG-Z1031, SDC1, NCT00265759

Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Other
Protocol IDs: EORTC-10951, PHARMACIA-EORTC-10951, NCT00002777

Phase III Randomized Study of Exemestane Versus Tamoxifen in Postmenopausal Women With Primary Breast Cancer Who Have Already Received 2-3 Years of Adjuvant Tamoxifen After Potentially Curable Surgery

Phase: Phase III
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor:
Protocol IDs: ICCG-96OEXE031-C1396-BIG9702, EORTC-10967, FRE-FNCLCC-PACS02/96OEXE031, EU-20013, EU-99002, ICCG-BIG-97/02, NCT00003418

Phase III Randomized Study of Adjuvant Exemestane Versus Adjuvant Tamoxifen in Postmenopausal Women With Early Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: CRC-TU-TEAM, EU-20149, ISRCTN75225940, NCT00032136

Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Premenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000316456, IBCSG 24-02, BIG 2-02, CALGB-IBCSG 24-02, CAN-NCIC-IBCSG 24-02, NCCTG-IBCSG 24-02, NSABP-IBCSG 24-02, SWOG-IBCSG 24-02, NABCI-IBCSG 24-02, UCLA-0403024-01, EU-20334, EUDRACT-2004-000166-13, NCT00066690

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Premenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000316458, IBCSG-25-02, BIG-3-02, NABCI-IBCSG-25-02, EU-20347, EUDRACT-2004-000168-28, NCT00066703

Suppression of Ovarian Function and Either Tamoxifen or Exemestane With or Without Chemotherapy in Treating Premenopausal Women With Resected Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Premenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000318832, IBCSG-26-02, BIG-4-02, NABCI-IBCSG-26-02, EU-20401, 2005-002626-59, EUDRACT-2005-002626-59, NCT00066807

10.

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9238IL/0048, EFECT, D6997C00048, NCT00065325

11.

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 35 and over
Sponsor: Other
Protocol IDs: MAP3, CAN-NCIC-MAP3, PFIZER-EXEAPO-0028-150, ExCel, CDR0000363802, NCT00083174

12.

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A5991048, NCT00143390

13.

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Phase: Phase III
Type: Treatment
Status: Completed
Age: 50 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 971-ONC-0028-081, A5991026, NCT00036270

14.

Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: CDR0000448616, ICR-CTSU-SOFEA, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422

15.

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 30 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 96-OEXE-031, A5991012, NCT00038467

16.

Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Alone Versus Ovarian Function Suppression and Tamoxifen Citrate Versus Ovarian Function Suppression and Exemestane in Premenopausal Women Who Have Undergone Surgery for Hormone Receptor-Positive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Premenopausal
Sponsor: Other
Protocol IDs: ICORG-06-02, ICORG 06-02, IBCSG 24-02, SOFT, BIG 2-02, EUDRACT-2004-000166-13, EU-20916, NCT00917969

17.

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001Y2301, 2008-008698-69, NCT00863655

18.

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9238UK/0005, NCT00944918

19.

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen

Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: NSABP B-33, CDR0000068640, ECOG-NSABP-B-33, NCT00016432

20.

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: MA27, CAN-NCIC-MA27, NCCTG-MA27, CALGB-CAN-NCIC-MA27, ECOG-CAN-NCIC-MA27, SWOG-CAN-NCIC-MA27, IBCSG-30-04, EUDRACT-2005-001893-28, CDR0000316325, CAN-NCIC-MA27-COMPANION, NCIC-MA.27, NCT00066573

21.

Phase I/II Randomized Study of Gamma-Secretase Inhibitor RO4929097 in Combination With Exemestane in Pre- and Postmenopausal Patients With Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MCC-8539, 8539, NCT01149356

22.

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: LCCC 2010-535, NCT01484041

23.

Phase II Study of Exemestane (an Aromatase Inhibitor) for Postmenopausal Women with Advanced Breast Cancer Refractory to Tamoxifen and Megestrol (Summary Last Modified 11/95)

Phase: Phase II
Type: Treatment
Status: Closed
Age: 25 to 90
Sponsor: Other
Protocol IDs: YALE-HIC-7480, NCI-V95-0725

24.

Phase II Study of Exemestane (an Aromatase Inhibitor) for Postmenopausal Women with Metastatic Breast Cancer Refractory to Tamoxifen (Summary Last Modified 10/95)

Phase: Phase II
Type: Treatment
Status: Closed
Age: postmenopausal
Sponsor:
Protocol IDs: YALE-HIC-7437, NCI-V95-0726

25.

Phase II Randomized Study of Exemestane and Raloxifene in Postmenopausal Women With a History of Stage 0 (Ductal Carcinoma in Situ), I, II, or III Breast Cancer Who Have No Clinical Evidence of Disease

Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-99017, NCI-G99-1662, NCT00004247

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®